157. スタージ・ウェーバー症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 8 / 薬物数 : 7 - (DrugBank : 4) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
Cannabidiol
Anne Comi, MD
2019 Phase 2 NCT04447846 United States
2014 Phase 1/Phase 2 NCT02332655 United States
Everolimus
Baylor College of Medicine
2014 Phase 2 NCT01997255 United States
Haemoblock
Center for Vascular Pathology, Moscow
2020 Phase 4 NCT04999618 Russian Federation
Modified atkins diet
Johns Hopkins University
2006 Phase 1 NCT00639730 United States
Sirolimus
Anne Comi, MD
2017 Phase 2/Phase 3 NCT03047980 United States
Timolol
Wills Eye
2012 Phase 1 NCT01533376 United States
Topical rapamycin
Clinica Universidad de Navarra, Universidad de Navarra
2011 Phase 2 NCT02080624 Spain
Anne Comi, MD
2019 Phase 2 NCT04447846 United States
2014 Phase 1/Phase 2 NCT02332655 United States
Everolimus
Baylor College of Medicine
2014 Phase 2 NCT01997255 United States
Haemoblock
Center for Vascular Pathology, Moscow
2020 Phase 4 NCT04999618 Russian Federation
Modified atkins diet
Johns Hopkins University
2006 Phase 1 NCT00639730 United States
Sirolimus
Anne Comi, MD
2017 Phase 2/Phase 3 NCT03047980 United States
Timolol
Wills Eye
2012 Phase 1 NCT01533376 United States
Topical rapamycin
Clinica Universidad de Navarra, Universidad de Navarra
2011 Phase 2 NCT02080624 Spain